[ad_1]
South China morning post
Sinovac Biotech’s CoronaVac vaccine is more than 50% effective, according to a Brazilian institute
A Covid-19 vaccine made by Sinovac Biotech was found to be more than 50 percent effective based on analysis of its late-stage trial conducted in Brazil, Reuters reported, citing Sao Paulo health officials. Institute on Wednesday, marks a big step forward for the Chinese-developed jab, one of the first in the global race for a Covid-19 vaccine, the doses of which have already been reserved by countries around the world. which is called CoronaVac, had reached the efficacy threshold set by Brazilian health regulator Anvisa, Butantan also said that Sinovac had asked for a delay in publishing accurate efficacy data of up to 15 days while the company consolidates data from global trials. , according to Reuters. who quoted Butantan director Dimas Covas as saying that none of those who participated in the trial developed a severe case of Covid-19. Get the latest insights and analysis from our Global Impact newsletter on the Big Stories Originated in China.CoronaVac began its phase three trials in Brazil in July, and has since expanded to other overseas test sites, including Turkey and Indonesia. Brazil is the first site to complete and report the results of its trial.The Sinovac vaccine provides a potentially significant advantage in the drive to bring vaccines to all corners of the world, as it uses an inactivated virus platform and can be stored at temperatures normal refrigerator. . This can make the two-dose vaccine more accessible to developing countries, compared to vaccines that require storage or transport at subzero temperatures, such as the mRNA vaccine from Pfizer and BioNTech. A handful of countries already have purchasing agreements with Sinovac for the doses, which include Brazil, Turkey, Indonesia, Singapore and Chile. Hong Kong will also receive 7.5 million doses of CoronaVac. Brazil is expected to purchase 46 million doses of CoronaVac, with the first batch to be delivered in November. Anvisa, Brazil’s National Health Surveillance Agency, issued Sinovac a certificate of good manufacturing practices on Monday, following an evaluation by Brazilian inspectors of the company’s CoronaVac vaccine factory in China. The Butantan Institute’s release of the trial results follows an announcement of interim data from a clinical trial of an inactivated vaccine from another Chinese company, state-owned Sinopharm. Months approved a vaccine developed by Sinopharm for general use, citing 86 percent efficacy in an interim analysis of a phase three trial. The full results have not yet been published. The Sinovac vaccine and two under Sinopharm received emergency use authorization in China in July, but both have yet to receive regulatory approval there for general use. At a news conference on Saturday, officials from the National Health Commission said regulators were receiving data from phase three trials from vaccine manufacturers on an ongoing basis. Meanwhile, an experimental coronavirus vaccine developed by the Chinese Academy of Sciences has been found to be safe and active. The candidate, developed in collaboration with Anhui Zhifei Longcom Biopharmaceutical, is the fifth vaccine developed in China to enter end-phase trials, and the first Chinese candidate to do so using the “protein subunit” method, using a single piece. purified virus selected for its ability to stimulate the immune response. The vaccine, called ZF2001, caused no serious adverse effects among the 950 participants in phase 1 and 2 trials, according to the researchers, and produced neutralizing antibodies, a critical component of immune defense, in at least 93 percent of those participants who received three course doses of the experimental vaccine. Leading American scientist Anthony Fauci receives Modern Covid-19 ZF2001 vaccine also elicited a “moderate” cellular immune response, another arm of the body’s defense believed to play a role in fighting the coronavirus that causes Covid- 19, the researchers said in a has not yet received peer review. “Our findings indicated that [the receptor binding domain]The protein subunit-based vaccine is safe and immunogenic. More clinical trials should be conducted to investigate its protective efficacy, ”said the authors, including George Gao, director of the Chinese Center for Disease Control and Prevention. The scientists cautioned that although the levels of neutralizing antibodies were higher than those seen in patients recovering from Covid-19, the efficacy of the coronavirus vaccine is still unknown. Additional report by Robert Delaney More from the South China Morning Post: * On the front lines of China’s coronavirus, not everyone wants a vaccine, at the moment * Coronavirus: more heat than light in search of the origin of Covid-19 * Coronavirus: 1 million Chinese injected with Sinopharm vaccine under emergency use scheme * Coronavirus vaccine trials in the US raise hopes that Chinese drugs will also be effective, says chief pharmacist. Brazilian Institute first appeared on South China Morning Post to get the latest news from South China Morning Post download our mobile application. Copyright 2020.
